Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
662 Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
